Key result
Type 2 diabetes linked to significantly lower heart rate variability and reduced BDNF vs controls.
Why the study?
Early detection of diabetic neuropathy is crucial to prevent severe complications and reduce healthcare burden, but sensitive early biomarkers are needed for type 2 diabetes mellitus-induced neuropathy.
Do heart rate variability parameters and serum BDNF/Nesfatin-1 levels differ in T2DM patients without clinical neuropathy compared to healthy controls?
Case-Control (n=60)
Yes
Do heart rate variability parameters and serum BDNF/Nesfatin-1 levels differ in T2DM patients without clinical neuropathy compared to healthy controls?
Standardized Mean Difference: 0.7
Absolute Event Rate: 36.63% vs 56.3%
p-value: p=0.00069
HRV parameters and serum BDNF levels are significantly reduced in T2DM patients prior to clinical evidence of neuropathy, suggesting their utility as sensitive biomarkers for early diabetic cardiac autonomic neuropathy.
Lower HRV and BDNF in T2DM may signal early autonomic changes; leaves open their value as predictors pending longitudinal validation.
Background: Early detection of diabetic neuropathy is crucial for both health and economic stability. Clinically, timely diagnosis and intervention can prevent the progression to severe complications, significantly preserving a patient's quality of life and mobility. Economically, this proactive approach reduces the long-term burden on healthcare systems. Objective: To assess and compare the early predictive value of different heart rate variability (HRV) parameters for the early detection of type 2 diabetes mellitus (T2DM)-induced neuropathy. And to evaluate their correlation with the novel serum parameters, Brain-Derived Neurotrophic Factor (BDNF), and Nesfatin-1. Results: HRV parameters showed early changes in type 2 diabetics, even before the development of overt neuropathy. We investigated early changes in heart rate variability parameters in a cohort of type 2 diabetic patients compared to age-matched healthy controls. We found that heart rate variability changes occur even before the development of neuropathic symptoms, suggesting that it can be used as an early detection measure in diabetic neuropathy. Also, we measured serum brain-derived neurotrophic factor and Nesfatine-1 in all study subjects and found brain-derived neurotrophic factor to show a stronger correlation with the HRV parameters than Nesfatine-1. This correlation was more significant in the diabetic patients than the healthy controls. Conclusion: We concluded that the HRV metrics can serve as sensitive early biomarkers for detecting type 2 diabetes mellitus-induced neuropathy, especially cardiac autonomic neuropathy, even in T2DM patients without clinical signs of neuropathy. Additionally, BDNF is superior to Nesfatin-1 for early detection of visceral autonomic neuropathy.
No takes yet. Share an insight, caveat, or question.
Alfaifi et al. (2026) conducted a case-control in Type 2 Diabetes Mellitus (n=60). Type 2 diabetes mellitus vs. Age-matched healthy controls was evaluated on Root Mean Square of Successive Differences (RMSSD) in heart rate variability (Cohen's d 0.7, p=0.00069). Patients with type 2 diabetes exhibited significantly lower heart rate variability (RMSSD Cohen's d 0.7) and reduced serum BDNF compared to healthy controls, suggesting early autonomic neuropathy.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: